Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An inspiring doctor and scientist of great compassion and intellect, Sir David Weatherall died 8 Dec 2018. A Nuffield Professor of Medicine, founder of the MRC Weatherall Institute of Molecular Medicine and a member of Wellcome’s Board throughout the 1990s, Sir David was instrumental in the creation of MORU back in 1979.

Personal Note from Nick White, SE Asia Chairman, MORU Tropical Network

Professor David Weatherall had the greatest influence on my professional life and for that I will be eternally grateful. I went to work for him as a young medical registrar at the Radcliffe Infirmary in Oxford in November 1977 (Tim Peto was my houseman!). Before I went to Oxford I had never heard of him – a reflection of my ignorance as he was already recognised as a brilliant scientist and an emerging leader in British academic medicine. I first met him (we all called him “Prof”) in his book lined office with old leathery chairs and a thick haze of aromatic pipe smoke. I said I wanted to work in the tropics one day, and he told me that he too was interested in tropical medicine and, if possible, would make it happen. He certainly did, and that is why we have a 40 year medical research collaboration based in Thailand and a younger unit in Vietnam.

“Prof” was a brilliant scientist and a perceptive, wise, witty, gentle, compassionate and inspiring physician. He would always enquire about his patient’s social circumstances, and he always examined them. This was an era when senior physicians and surgeons often felt and acted as if they were on a higher plane than the remainder of humanity. David Weatherall hated all that pomp and flummery. He treated everyone as equals. He had a sharp wit, an open and enquiring mind, and he took genuine satisfaction and pride in the success of others. “Prof” inspired and supported a generation of young physicians and scientists. He became the UK’s leading academic clinician, a towering figure in the molecular medicine revolution, an internationally acclaimed scientist, and he was showered with honours and accolades – but his character never changed.

In the late 1970s the Wellcome Trust were seeking to set up a new tropical medicine research unit in East Asia. David Weatherall and Peter Williams (then the Director of the Wellcome Trust) visited several potential collaborating institutions. The Faculty of Tropical Medicine, Mahidol University were interested in this idea and so the Bangkok unit began in 1979 as a collaboration between the Faculty and the Nuffield Department of Medicine, Oxford University headed by David Weatherall. David and Mary Warrell came out to start the research work and I joined them the following year. “Prof” supported us through good times and bad, and although we were successful on the scientific front there were bad times too. We came under a lot of pressure in the late 1980s and I thought we might have to close the Unit and leave Thailand. This led to the founding of the Vietnam unit. David Weatherall in Oxford and Bridget Ogilvie at the Wellcome Trust gave us unwavering support throughout those hard times. Without that we would not have MORU today.

I kept “Prof” up to date with everything that happened in our Unit, and our research progress because he was always interested and encouraging, and he invariably gave wise advice. For such a brilliant mind he was interestingly averse to communications technology – he never mastered computers or e-mail, preferring written letters and personal meetings. As far as I know he never possessed a mobile ‘phone! In scientific and clinical meetings, he would close his eyes, and appear to be completely asleep, but as soon as the speaker stopped he would open his eyes and ask pertinent questions! He was a determined pipe smoker – and on two occasions I witnessed smoke billowing from the pocket of his white coat! Long after he retired I would visit him whenever I was in Oxford to report as he wanted to know how we in MORU were getting on, what advances we had made, and whether there was anything he could do to help. He had a great affection for Thailand, sharing research interests on the study and management of haemoglobinopathies, collaborating with leading figures in Thai medical research, and later advising the Prince Mahidol Award foundation. He was very happy to see the research progress, and particularly the translation to human benefit, and also the career progression of young investigators from Thailand and neighbouring countries. We certainly owe him a lot.

He was a very great man.

You can read Sir David’s recollections of how MORU came about, and also what Wellcome and the University of Oxford say about Sir David’s remarkable career.

Similar stories

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

MORU Bangkok Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

MORU Bangkok

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

MORU Bangkok Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.